US firm Abraxis BioSciences anti-cancer drug 'Abraxane', was denied patent by Indian Patent Office based on Sec3(d)- the provision which led Novartis to lose its flagship drug Glilvec last year. This decision may boost generic production of the said drug.
The US Pharma major has right to appeal IPBA or file a writ Petition in High Court. Domestic company Natco had filed an opposition before the patent was issued to the US firm. Natco's version, Albupax, was the first indigenously developed nanotech-based cancer drug.